In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

Q2 2025 Management View Martin H. Huber, President, CEO & Director, opened by highlighting the progress on Emi-Le, the company's Dolasynthen ADC targeting B7-H4, emphasizing oral presentations at ASCO ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

Shares of GSK PLC GSK slid 3.04% to £14.18 Thursday, on what proved to be an all-around rough trading session for the stock ...

GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.01% to 9,136.94. GSK PLC ...